These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 36813118)

  • 1. Autoantibodies enhance ADAMTS-13 clearance in patients with immune thrombotic thrombocytopenic purpura.
    Underwood MI; Alwan F; Thomas MR; Scully MA; Crawley JTB
    J Thromb Haemost; 2023 Jun; 21(6):1544-1552. PubMed ID: 36813118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADAMTS-13 conformation influences autoimmune recognition in immune thrombotic thrombocytopenic purpura.
    Underwood MI; Thomas MR; Scully MA; Crawley JTB
    J Thromb Haemost; 2024 Apr; 22(4):1069-1079. PubMed ID: 38160729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of N-glycan mediated shielding of ADAMTS-13 on the binding of pathogenic antibodies in immune thrombotic thrombocytopenic purpura.
    Postmus T; Graça NAG; Ferreira de Santana J; Ercig B; Langerhorst P; Luken B; Joly BS; Vanhoorelbeke K; Veyradier A; Coppo P; Voorberg J
    J Thromb Haemost; 2023 Dec; 21(12):3402-3413. PubMed ID: 37633643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism underlying severe deficiency of plasma ADAMTS-13 activity in immune thrombotic thrombocytopenic purpura.
    Zheng XL
    J Thromb Haemost; 2024 May; 22(5):1358-1365. PubMed ID: 38360215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.
    Shelat SG; Smith P; Ai J; Zheng XL
    J Thromb Haemost; 2006 Aug; 4(8):1707-17. PubMed ID: 16879212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Cell Directed Therapy for Immune Thrombotic Thrombocytopenic Purpura (iTTP).
    Chen M; Shortt J
    Transfus Med Rev; 2022 Oct; 36(4):204-214. PubMed ID: 36396570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report.
    Schwaegermann MK; Hobohm L; Rausch J; Reuter M; Griemert TF; Sivanathan V; Falter T; Sprinzl MF; Lackner KJ; Galle PR; Konstantinides S; Theobald M; von Auer C
    Hamostaseologie; 2023 Jun; 43(3):215-218. PubMed ID: 34327693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy.
    Mingot-Castellano ME; García-Candel F; Martínez-Nieto J; García-Arroba J; de la Rubia-Comos J; Gómez-Seguí I; Paciello-Coronel ML; Valcárcel-Ferreiras D; Jiménez M; Cid J; Lozano M; García-Gala JM; Angós-Vazquez S; Vara-Pampliega M; Guerra-Domínguez L; Ávila-Idrobo LF; Oliva-Hernandez A; Zalba-Marcos S; Tallón-Ruiz I; Ortega-Sánchez S; Goterris-Viciedo R; Moreno-Jiménez G; Domínguez-Acosta L; Araiz-Ramírez M; Hernández-Mateos L; Flores-Ballesteros E; Del Río-Garma J; Pascual-Izquierdo C
    Blood; 2024 May; 143(18):1807-1815. PubMed ID: 38237147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refining the standard of care in immune thrombotic thrombocytopenic purpura.
    Laurence J
    Clin Adv Hematol Oncol; 2024 Oct; 22(8):381-391. PubMed ID: 39356816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADAMTS13 conformations and mechanism of inhibition in immune thrombotic thrombocytopenic purpura.
    Halkidis K; Zheng XL
    J Thromb Haemost; 2022 Oct; 20(10):2197-2203. PubMed ID: 35842925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura.
    Völker LA; Kaufeld J; Balduin G; Merkel L; Kühne L; Eichenauer DA; Osterholt T; Hägele H; Kann M; Grundmann F; Kolbrink B; Schulte K; Gäckler A; Kribben A; Boss K; Potthoff SA; Rump LC; Schmidt T; Mühlfeld AS; Schulmann K; Hermann M; Gaedeke J; Sauerland K; Bramstedt J; Hinkel UP; Miesbach W; Bauer F; Westhoff TH; Bruck H; Buxhofer-Ausch V; Müller TJ; Wendt R; Harth A; Schreiber A; Seelow E; Tölle M; Gohlisch C; Bieringer M; Geuther G; Jabs WJ; Fischereder M; von Bergwelt-Baildon A; Schönermarck U; Knoebl P; Menne J; Brinkkoetter PT;
    J Thromb Haemost; 2023 Mar; 21(3):559-572. PubMed ID: 36696206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.
    Thomas MR; de Groot R; Scully MA; Crawley JT
    EBioMedicine; 2015 Aug; 2(8):942-52. PubMed ID: 26425702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study.
    Schieppati F; Russo L; Marchetti M; Barcella L; Cefis M; Gomez-Rosas P; Caldara G; Carpenedo M; D'Adda M; Rambaldi A; Savignano C; Billio A; Bruno Franco M; Toschi V; Falanga A
    Am J Hematol; 2020 Aug; 95(8):953-959. PubMed ID: 32350923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023.
    Matsumoto M; Miyakawa Y; Kokame K; Ueda Y; Wada H; Higasa S; Yagi H; Ogawa Y; Sakai K; Miyata T; Morishita E; Fujimura Y;
    Int J Hematol; 2023 Nov; 118(5):529-546. PubMed ID: 37689812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment Strategies.
    Mazepa MA; Park YA; Raval JS
    Transfus Med Rev; 2019 Oct; 33(4):248-255. PubMed ID: 31645275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS-13 activity levels in inhibitor-treated rats by the use of defined doses of recombinant ADAMTS-13.
    Plaimauer B; Schiviz A; Kaufmann S; Höllriegl W; Rottensteiner H; Scheiflinger F
    J Thromb Haemost; 2015 Nov; 13(11):2053-62. PubMed ID: 26340698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura do not hamper ELISA-based quantification of ADAMTS13 antigen.
    Dekimpe C; Roose E; Tersteeg C; Joly BS; Dewaele A; Horta S; Pareyn I; Vandenbulcke A; Deckmyn H; Feys HB; Tellier E; Kaplanski G; Scully M; Coppo P; De Meyer SF; Veyradier A; Vanhoorelbeke K
    J Thromb Haemost; 2020 Apr; 18(4):985-990. PubMed ID: 31989742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A human monoclonal antibody against the distal carboxyl terminus of ADAMTS-13 modulates its susceptibility to an inhibitor in thrombotic thrombocytopenic purpura.
    Halkidis K; Siegel DL; Zheng XL
    J Thromb Haemost; 2021 Aug; 19(8):1888-1895. PubMed ID: 33834592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADAMTS13 Biomarkers in Management of Immune Thrombotic Thrombocytopenic Purpura.
    Sui J; Zheng L; Zheng XL
    Arch Pathol Lab Med; 2023 Aug; 147(8):974-979. PubMed ID: 36223210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of inhibition of human monoclonal antibodies in immune thrombotic thrombocytopenic purpura.
    Halkidis K; Meng C; Liu S; Mayne L; Siegel DL; Zheng XL
    Blood; 2023 Jun; 141(24):2993-3005. PubMed ID: 37023370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.